FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Steven O'Day

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Anatomy

Circulating Neoplastic Cells

Physiology

Disease Progression

Co-author Network

Publications

TOP 3
Steven J O'Day; Caroline Robert; Jacob Schachter; Alessandro Testori; Selma Ugurel; Vojo Vukovic; Richard Kefford; Joelle Lufkin; Jacek Mackiewicz; Laurent Mortier; Safi Bahcall; Vanna Chiarion-Sileni; Frances Collichio; Alexander M M Eggermont; Philip Friedlander; Claus Garbe; Jean Jacques Grob; Wei Guo; Axel Hauschild
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma.
Steven J O'Day; Anna C Pavlick; Manjula Reddy; Heidi Schalch; Omid Hamid; Zhihui Lang; Jie Ling; Marielena Mata; Mark R Albertini; Brenda Foster
Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma.
Gerald S Falchook; Omid Hamid; Jeffrey R Infante; Tobias H Arkenau; Samuel C Blackman; Michael P Brown; C Martin Curtis; Kevin B Kim; Razelle Kurzrock; Peter Lebowitz; Georgina V Long; Bo Ma; Michael Millward; Steven J O'Day; Daniele Ouellet; Anna C Pavlick; Richard F Kefford
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Steven O'Day (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Steven J O'Day; Caroline Robert; Jacob Schachter; Alessandro Testori; Selma Ugurel; Vojo Vukovic; Richard Kefford; Joelle Lufkin; Jacek Mackiewicz; Laurent Mortier; Safi Bahcall; Vanna Chiarion-Sileni; Frances Collichio; Alexander M M Eggermont; Philip Friedlander; Claus Garbe; Jean Jacques Grob; Wei Guo; Axel Hauschild
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(9):1211-8.
2012: Steven J O'Day; Anna C Pavlick; Manjula Reddy; Heidi Schalch; Omid Hamid; Zhihui Lang; Jie Ling; Marielena Mata; Mark R Albertini; Brenda Foster
Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma.
Investigational new drugs 2012;30(3):1074-81.
2012: Gerald S Falchook; Omid Hamid; Jeffrey R Infante; Tobias H Arkenau; Samuel C Blackman; Michael P Brown; C Martin Curtis; Kevin B Kim; Razelle Kurzrock; Peter Lebowitz; Georgina V Long; Bo Ma; Michael Millward; Steven J O'Day; Daniele Ouellet; Anna C Pavlick; Richard F Kefford
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
Lancet 2012;379(9829):1893-901.
2012: David R Minor; Steven J O'Day; Maria Garrido; Omid Hamid; Mohammed Kashani-Sabet; Boris C Bastian
Sunitinib therapy for melanoma patients with KIT mutations.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(5):1457-63.
2011: Omid Hamid; Peter D Boasberg; Katherine Rosenthal; Steven J O'Day
Systemic treatment of metastatic melanoma: new approaches.
Journal of surgical oncology 2011;104(4):425-9.
2011: Evan M Hersh; Steven J O'Day; John Powderly; Khuda D Khan; Anna C Pavlick; Lee D Cranmer; Wolfram E Samlowski; Geoffrey M Nichol; Michael J Yellin; Jeffrey S Weber
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma.
Investigational new drugs 2011;29(3):489-98.
2010: Steven J O'Day; M Maio; V Chiarion-Sileni; T F Gajewski; H Pehamberger; I N Bondarenko; P Queirolo; L Lundgren; S Mikhailov; L Roman; C Verschraegen; R Humphrey; R Ibrahim; V de Pril; A Hoos; Jedd D Wolchok
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(8):1712-7.
2010: Kazuo Koyanagi; Steven J O'Day; Peter D Boasberg; Michael B Atkins; He-Jing Wang; Rene Gonzalez; Karl Lewis; John A Thompson; Clay M Anderson; Jose Lutzky; Thomas T Amatruda; Evan M Hersh; Jon Richards; Jeffrey S Weber; Dave S B Hoon
Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(8):2402-8.
2007: Tomislav Dragovich; Michael S Gordon; David S Mendelson; Lucas Wong; Manuel Modiano; H-H Sherry Chow; Betty K Samulitis; Steven J O'Day; Kathryn Grenier; Evan M Hersh; Robert T Dorr
Phase I trial of imexon in patients with advanced malignancy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(13):1779-84.
2007: Masaru Shinozaki; Steven J O'Day; Minoru Kitago; Farin Amersi; Christine Kuo; Joseph Kim; He-Jing Wang; Dave S B Hoon
Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(7):2068-74.
2006: Peter D Boasberg; Dave S B Hoon; Lawrence D Piro; Maureen A Martin; Akhide Fujimoto; Timothy S Kristedja; Sandeep Bhachu; Xing Ye; Regina Deck; Steven J O'Day
Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma.
The Journal of investigative dermatology 2006;126(12):2658-63.
2006: Takuji Mori; Steve Martinez; Steven J O'Day; Donald L Morton; Naoyuki Umetani; Minoru Kitago; Atsushi Tanemura; Sandy L Nguyen; Andy N Tran; He-Jing Wang; Dave S B Hoon
Estrogen receptor-alpha methylation predicts melanoma progression.
Cancer research 2006;66(13):6692-8.
2006: Karl D Lewis; William A Robinson; Martin D McCarter; Nathan W Pearlman; Steven J O'Day; Clay Anderson; Thomas T Amatruda; Anna Baron; Chan Zeng; Maude Becker; Susan Dollarhide; Karen Matijevich; Rene Gonzalez
Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):3157-63.
2006: Kazuo Koyanagi; Takuji Mori; Steven J O'Day; Steve Martinez; He-Jing Wang; Dave S B Hoon
Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients.
Cancer research 2006;66(12):6111-7.
2006: Steven J O'Day; Peter D Boasberg
Management of metastatic melanoma 2005.
Surgical oncology clinics of North America 2006;15(2):419-37.
2006: Kazuo Koyanagi; Steven J O'Day; Rene Gonzalez; Karl Lewis; William A Robinson; Thomas T Amatruda; Christine Kuo; He-Jing Wang; Robert Milford; Donald L Morton; Dave S B Hoon
Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(4):1137-43.
2006: Karl D Lewis; John A Thompson; Jeffrey S Weber; William A Robinson; Steven J O'Day; Jose Lutzky; Sewa S Legha; Simon Floret; Francis Ruvuna; Rene Gonzalez
A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma.
Investigational new drugs 2006;24(1):89-94.
2005: Takuji Mori; Steven J O'Day; Naoyuki Umetani; Steve Martinez; Minoru Kitago; Kazuo Koyanagi; Christine Kuo; Teh-Ling Takeshima; Robert Milford; He-Jing Wang; Vu D Vu; Sandy L Nguyen; Dave S B Hoon
Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9351-8.
2005: Robert W Weber; Steven J O'Day; Madalene Rose; Regina Deck; Patricia Ames; James Good; John Meyer; Robert Allen; Sharon Trautvetter; Molly Timmerman; Scott Cruickshank; Mary Cook; Rene Gonzalez; Lynn E Spitler
Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(35):8992-9000.
2005: Kazuo Koyanagi; Steven J O'Day; Rene Gonzalez; Karl Lewis; William A Robinson; Thomas T Amatruda; He-Jing Wang; Robert Elashoff; Hiroya Takeuchi; Naoyuki Umetani; Dave S B Hoon
Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(31):8057-64.
2005: Kazuo Koyanagi; Christine Kuo; Taku Nakagawa; Takuji Mori; Hideaki Ueno; Arnulfo R Lorico; He-Jing Wang; Eddie Hseuh; Steven J O'Day; Dave S B Hoon
Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients.
Clinical chemistry 2005;51(6):981-8.
2005: Dongxin Liu; Steven J O'Day; Dongyun Yang; Peter D Boasberg; Robert Milford; Timothy S Kristedja; Susan Groshen; Jeffrey Weber
Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(3):1237-46.
2005: Karl D Lewis; Peter Gibbs; Steven J O'Day; Jon Richards; Jeffrey Weber; Clay Anderson; Chan Zeng; Anna Baron; Paul Russ; Rene Gonzalez
A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
Cancer investigation 2005;23(4):303-8.
2004: Akihide Fujimoto; Steven J O'Day; Bret Taback; David Elashoff; Dave S B Hoon
Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts disease outcome.
Cancer research 2004;64(12):4085-8.
2004: Bret Taback; Steven J O'Day; Dave S B Hoon
Quantification of circulating DNA in the plasma and serum of cancer patients.
Annals of the New York Academy of Sciences 2004;1022():17-24.
2004: Reiko F Irie; David W Ollila; Steven J O'Day; Donald L Morton
Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma.
Cancer immunology, immunotherapy : CII 2004;53(2):110-7.
2004: Bret Taback; Steven J O'Day; Peter D Boasberg; Sherry Shu; Patricia Fournier; Robert Elashoff; He-Jing Wang; Dave S B Hoon
Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma.
Journal of the National Cancer Institute 2004;96(2):152-6.
2003: Steven J O'Day; Sanjiv S Agarwala; Peter Naredi; Carrie L Kass; Kurt Gehlsen; John Glaspy
Treatment with histamine dihydrochloride and interleukin-2 in patients with advanced metastatic malignant melanoma: a detailed safety analysis.
Melanoma research 2003;13(3):307-11.
2003: Peter D Boasberg; Steven J O'Day; Timothy S Kristedja; Maureen Martin; Hejing Wang; Regina Deck; Kelly Shinn; Patricia Ames; Beth Tamar; Zbigniew Petrovich
Biochemotherapy for metastatic melanoma with limited central nervous system involvement.
Oncology 2003;64(4):328-35.
2002: Zbigniew Petrovich; Cheng Yu; Steven L Giannotta; Steven J O'Day; Michael L J Apuzzo
Survival and pattern of failure in brain metastasis treated with stereotactic gamma knife radiosurgery.
Journal of neurosurgery 2002;97(5 Suppl):499-506.
2002: Eddy C Hsueh; Richard Essner; Leland J Foshag; David W Ollila; Guy Gammon; Steven J O'Day; Peter D Boasberg; Stacey L Stern; Xing Ye; Donald L Morton
Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(23):4549-54.
2002: Donald L Morton; Eddy C Hsueh; Richard Essner; Leland J Foshag; Steven J O'Day; Anton J Bilchik; Rishab K Gupta; Dave S B Hoon; Mepur H Ravindranath; J Anne Nizze; Guy Gammon; Leslie A Wanek; He-Jing Wang; Robert Elashoff
Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.
Annals of surgery 2002;236(4):438-48; discussion 448-9.
2002: Steven J O'Day; Peter D Boasberg; Lawrence Piro; Timothy S Kristedja; He-Jing Wang; Maureen Martin; Regina Deck; Patricia Ames; Kelly Shinn; Hannah Kim; Patricia Fournier; Guy Gammon
Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(9):2775-81.
2002: L Andrew DiFronzo; Rishab K Gupta; Richard Essner; Leland J Foshag; Steven J O'Day; Leslie A Wanek; Stacey L Stern; Donald L Morton
Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(15):3242-8.
2002: Mark R Middleton; Mark Sarno; Sanjiv S Agarwala; John Glaspy; Aziz Laurent; Kelly M McMasters; Peter Naredi; Steven J O'Day; Eric Whitman; Sarah Danson; Rebecca Cosford; Kurt Gehlsen
Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2.
Journal of clinical pharmacology 2002;42(7):774-81.
2002: Cheng Yu; Joseph C T Chen; Michael L J Apuzzo; Steven J O'Day; Steven L Giannotta; Jeffrey S Weber; Zbigniew Petrovich
Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery.
International journal of radiation oncology, biology, physics 2002;52(5):1277-87.
2002: Sanjiv S Agarwala; John Glaspy; Steven J O'Day; Malcolm Mitchell; John C Gutheil; Eric Whitman; Rene Gonzalez; Evan M Hersh; Lynn Feun; Robert Belt; Frank Meyskens; Kristoffer Hellstrand; Diana Wood; John M Kirkwood; Kurt Gehlsen; Peter Naredi
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):125-33.
2001: Steven J O'Day; Peter D Boasberg; Timothy S Kristedja; Maureen Martin; He-Jing Wang; Patricia Fournier; M Cabot; Michael W DeGregorio; Guy Gammon
High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma.
Cancer 2001;92(3):609-19.
2001: Mepur H Ravindranath; Alexandra Gonzales; Daniel Soh; K Nishimoto; WY Tam; Anton J Bilchik; Donald L Morton; Steven J O'Day
Interleukin-2 binds to ganglioside GD(1b).
Biochemical and biophysical research communications 2001;283(2):369-73.
2001: Bret Taback; Donald L Morton; Steven J O'Day; D H Nguyen; T Nakayama; Dave S B Hoon
The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2001;158():78-92.
2000: Joseph C T Chen; Zbigniew Petrovich; Steven J O'Day; D Morton; Richard Essner; Steven L Giannotta; Cedric Yu; Michael L J Apuzzo
Stereotactic radiosurgery in the treatment of metastatic disease to the brain.
Neurosurgery 2000;47(2):268-79; discussion 279-81.
1999: Steven J O'Day; Guy Gammon; Peter D Boasberg; M A Martin; Timothy S Kristedja; Mingzhou Guo; S Stern; S Edwards; Patricia Fournier; M Weisberg; M Cannon; N W Fawzy; T D Johnson; Richard Essner; Leland J Foshag; Donald L Morton
Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(9):2752-61.
1999: Joseph C T Chen; Steven J O'Day; D Morton; Richard Essner; A Cohen-Gadol; Dana M MacPherson; Steven L Giannotta; Zbigniew Petrovich; Cedric Yu; Michael L J Apuzzo
Stereotactic radiosurgery in the treatment of metastatic disease to the brain.
Stereotactic and functional neurosurgery 1999;73(1-4):60-3.
1999: Sean D Lavine; Zbigniew Petrovich; A A Cohen-Gadol; LS Masri; D L Morton; Steven J O'Day; Richard Essner; Vladimir Zelman; Cedric Yu; Gary Luxton; Michael L J Apuzzo
Gamma knife radiosurgery for metastatic melanoma: an analysis of survival, outcome, and complications.
Neurosurgery 1999;44(1):59-64; discussion 64-6.